Trial Profile
Phase I, Single-Center, Open Label Trial of Ublituximab + Glucocorticoids for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Methylprednisolone (Primary) ; Ublituximab (Primary)
- Indications Neuromyelitis optica; Optic neuritis
- Focus Adverse reactions; Proof of concept
- Sponsors TG Therapeutics Inc
- 05 Jun 2019 Status changed from active, no longer recruiting to completed.
- 01 Jun 2019 Results of safety study of ublituximab in acute relapses of neuromyelitis optica spectrum disorder published in the Medicine
- 27 Sep 2018 Planned End Date changed from 28 Jul 2018 to 28 Jul 2019.